Screener
Amgen AMGN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Less: | ||||
| Manufacturing cost of sales(1)(2) | 2,139 | 2,484 | 4,319 | 5,012 |
| Profit share and royalties in cost of sales(1) | 672 | 527 | 1,236 | 967 |
| Research and development(1) | 1,868 | 1,744 | 3,587 | 3,230 |
| Sales and marketing(1) | 1,155 | 1,137 | 2,289 | 2,203 |
| General and administrative(1) | 590 | 554 | 1,058 | 1,175 |
| Other segment items(3) | 314 | 557 | 227 | (5) |
| Interest income | (125) | (86) | (226) | (212) |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's business segments — R&D?
- Amgen (AMGN) reported business segments — R&D of $1.87B in Q2 2026.
- How has Amgen's business segments — R&D changed year-over-year?
- Amgen's business segments — R&D increased by 7.1% year-over-year, from $1.74B to $1.87B.
- What does business segments — R&D mean?
- Captures the investment in discovery, clinical trials, and regulatory processes required to bring new therapeutic candidates to market. This is the primary driver of long-term growth and pipeline viability for a biotechnology company. It reflects the company's commitment to innovation and future revenue streams.
Ask your AI about Amgen's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude